Shionogi, a top 50 big pharma company will take a 10 percent stake in Viiv Healthcare, a AIDS drug joint venture between GlaxoSmithKline and Pfizer in a pharma partnering pact, in exchange for its rights to the drug Dolutegravir.
Shionogi, which will retain intellectual property rights to the drug, will gain one Viiv board seat and receive royalties of 15 percent to 19 percent on sales of Dolutegravir and related products.
Financial terms of the pharma partnering pact were not disclosed.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Shionogi
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity